Alternating gemcitabine and cisplatin with gemcitabine and radiation in stage IV squamous cell carcinoma of the head and neck

Annals of Oncology

Volumn 15, Issue 4, 2004, Pages 646-652

  Benasso, Marco ^a   Corvo R ^a   Ponzanelli, A ^a   Sanguineti, G ^a   Ricci, I ^a   Pallestrini, E ^a   Santelli, A ^a   Vitale, V ^a   Rosso, R ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Chemo radiotherapy; Gemcitabine; Head and neck; Squamous cell carcinoma; Stage IV

Indexed keywords

CISPLATIN; DEXAMETHASONE; FLUOROURACIL; GEMCITABINE; GRANISETRON; METOCLOPRAMIDE; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DOSE RESPONSE; FEASIBILITY STUDY; FEMALE; FEVER; FOLLOW UP; HEAD AND NECK CARCINOMA; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MUCOSAL NECROSIS; NEUTROPENIA; PARENTERAL NUTRITION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SEPSIS; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUBE FEEDING; ULCER; WEIGHT REDUCTION; XEROSTOMIA;

EID: 2342438685     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh138     Document Type: Article

References (23)

1. Forastiere A, Koch W, Trotti A et al. Head and neck cancer. N Engl J Med 2001; 26: 1890-1900.
2. Pignon JP, Bourhis J, Domenge C et al. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet 2000; 355: 949-955.
3. Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation radiotherapy and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinoma: preliminary reports of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 7-16.
4. Adelstein DJ, Saxton JP, Lavertu P et al. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol 2002; 20: 1405-1410.
5. Vokes EE, Kies MS, Haraf DJ et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000; 18: 1652-1661.
6. Vokes EE, Stenson K, Rosen FR et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003; 21: 320-326.
7. Merlano M, Vitale V, Rosso R et al. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med 1992; 327: 1115-1121.
8. Merlano M, Benasso M, Corvò R et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996; 88: 583-589.
9. Corvò R, Benasso M, Sanguineti G et al. Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Cancer 2001; 92: 2856-2867.
10. Braakhuis BJ, van Dongen GA, Vermorken JB et al. Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine against human head and neck cancer. Cancer Res 1991; 51: 211-214.
11. Catimel G, Vermorken JB, Clavel M et al. A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 543-547.
12. Peters GJ, Bergman AM, Ruiz van Haperen VWT et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995; 22: 72-79.
13. Hitt R, Castellano D, Hidalgo M et al. Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck. Ann Oncol 1998; 9: 1347-1349.
14. Shewach DS, Lawrence TS. Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs 1996; 14: 257-263.
15. Eisbruch A, Shewach DS, Bradford CR et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol 2001; 19: 792-799.
16. Benasso M, Merlano, M, Sanguineti G et al. Gemcitabine, cisplatin, and radiation for advanced, unresectable squamous cell carcinoma of the head and neck. A feasibility study. Am J Clin Oncol 2001; 24: 618-622.
17. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
18. Ang KK, Kaander JHAM, Peters LJ. Radiotherapy for head and neck cancers. Philadelphia, PA: Lea & Febiger 1994.
19. Thall PF, Simon R, Ellenberg SS. A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 1989; 45: 537-547.
20. Kaplan EL, Meyer P. Non-parametric estimation for incomplete observation. J Am Stat Assoc 1958; 53: 457-474.
21. LENT SOMA scales for all anatomic sites. Int J Radiat Oncol Biol Phys 1995; 31: 1049-1092.
22. Adelstein DJ, Li Y, Adams GL et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-98.
23. Benasso M, Lionetto R, Corvò R et al. Impact of the treating institution on the survival of patients with head and neck cancer treated with concomitant alternating chemotherapy and radiation. Eur J Cancer 2003; 39: 1895-1898.